In this article

LLY

Follow your favorite stocks CREATE FREE ACCOUNT

Eli Lilly on Thursday said its next-generation obesity drug delivered what appears to be the highest weight loss yet in a late-stage trial while reducing knee arthritis pain, clearing the first of several upcoming studies on the weekly injection.

The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment. When evaluating only patients who stayed on the drug, the highest dose delivered 28.7% weight loss on average.

The company said some patients lost so much weight that they decided to drop out of the trial.

"It's incredible," said Dr. Caroline

See Full Page